Items where authors include "McMenemin, R."

Article

Brown, J.E. orcid.org/0000-0003-4960-3032, Royle, K.-L., Gregory, W. et al. (96 more authors) (2023) Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial. The Lancet Oncology, 24 (3). pp. 213-227. ISSN 1470-2045

Eisen, T., Frangou, E., Oza, B. et al. (22 more authors) (2020) Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial. Journal of Clinical Oncology, 38 (34). pp. 4064-4075. ISSN 0732-183X

Faivre-Finn, C., Snee, M., Ashcroft, L. et al. (17 more authors) (2017) Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. The Lancet Oncology, 18 (8). pp. 1116-1125. ISSN 1470-2045

Hussain, S.A. orcid.org/0000-0003-1552-511X, Ansari, J., Huddart, R. et al. (10 more authors) (2017) VICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium: A retrospective analysis of the use of vinflunine in multi-centre real life setting as second line chemotherapy through Free of Charge Programme for patients in the UK and Ireland. International Journal of Oncology, 50 (3). pp. 768-772. ISSN 1791-2423